Only the highest MET expression by IHC (i.e., 3+) was predictive of response in this study and the ORR for the MET-overexpressing 3+ cases was 32%, thus noticeably lower than the ORR of >50% observed when targeting selected patient subpopulations harboring other NSCLC-drivers such as EGFR-, ALK-, ROS1- or BRAF-mutants [135]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.